Senior Scientist, Protein Analytics

Hillstar Bio, a precision immunology company that recently completed a sizable Series A financing with a syndicate of blue chip investors (Droia, Frazier, Novo, LifeArc).

Hillstar aspires to build a portfolio of programs against autoimmune diseases with unmet or underserved medical needs. Its lead program is an antibody designed to selectively target a root cause of Cold Agglutinin Disease (CAD) and Systemic Lupus Erythematosus (SLE). CAD is a chronic, rare (incidence 15/million) but debilitating condition with high morbidity (anemia, fatigue, cold-induced circulatory symptoms). SLE on the other hand, affects an estimated 3 million adults worldwide, with symptoms affecting various organs including joints, kidneys, blood cells, brain, heart, and lungs. Existing treatment options for CAD and SLE have limited effectiveness, carry considerable safety risks, and fail to address key disease symptoms in a large proportion of patients, leading to significant chronic morbidity and...